A61K 9/4866
Organic macromolecular compounds
Official title: {Organic macromolecular compounds}
A61K9/4866 (Organic macromolecular compounds) appears on 2,131 US grants and 4,095 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,131
- Published applications
- 4,095
- Assignees
- 1,633
- Inventors
- 6,832
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 0 | 0 |
| 1978 | 2 | 0 |
| 1979 | 2 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 2 | 0 |
| 1985 | 1 | 0 |
| 1986 | 3 | 0 |
| 1987 | 7 | 0 |
| 1988 | 6 | 0 |
| 1989 | 12 | 0 |
| 1990 | 4 | 0 |
| 1991 | 7 | 0 |
| 1992 | 7 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 4 | 0 |
| 1996 | 10 | 0 |
| 1997 | 6 | 0 |
| 1998 | 6 | 0 |
| 1999 | 21 | 0 |
| 2000 | 9 | 0 |
| 2001 | 21 | 11 |
| 2002 | 21 | 32 |
| 2003 | 21 | 79 |
| 2004 | 18 | 68 |
| 2005 | 25 | 78 |
| 2006 | 22 | 82 |
| 2007 | 10 | 71 |
| 2008 | 14 | 86 |
| 2009 | 10 | 96 |
| 2010 | 31 | 101 |
| 2011 | 32 | 102 |
| 2012 | 55 | 137 |
| 2013 | 73 | 160 |
| 2014 | 90 | 199 |
| 2015 | 122 | 220 |
| 2016 | 131 | 246 |
| 2017 | 145 | 257 |
| 2018 | 126 | 225 |
| 2019 | 164 | 234 |
| 2020 | 142 | 256 |
| 2021 | 152 | 291 |
| 2022 | 143 | 242 |
| 2023 | 111 | 211 |
| 2024 | 124 | 248 |
| 2025 | 120 | 214 |
| 2026 | 88 | 149 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- API stability in softgels29 Sep 2026US 12,746,206 B2R.P. Scherer Technologies, LLC
- Cabozantinib compositions and methods of use22 Sep 2026US 12,741,938 B2Handa Oncology, LLC
- Pharmaceutical preparation and method for producing the same15 Sep 2026US 12,734,163 B2Fuji Pharma Co., Ltd.
- Chronic kidney disease treatment or prevention method1 Sep 2026US 12,721,844 B2Shionogi & Co., Ltd.
- Psilocybin compositions, methods of making and methods of using the same1 Sep 2026US 12,721,856 B2Compass Pathfinder Limited
- Formulations containing tryptamine derivatives and uses thereof8 Oct 2026US 2026/0306453 A1Psilera Inc.
- Hydrogel ink, hydrogel and uses thereof8 Oct 2026US 2026/0306528 A1
- A floating drug delivery system for solid forms of salts used in bowel cleansing products8 Oct 2026US 2026/0306534 A1Dark Canyon Laboratories, LLC
- Production of a pharmaceutical dosage form from horseradish and nasturtium8 Oct 2026US 2026/0306570 A1Kwizda Pharma GmbH
- Cannabidiol formulations1 Oct 2026US 2026/0294812 A1Dsm IP Assets B.V.
Most cited
By later US patents
- Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation733US 9,101,621 B2Celgene Corporation · 2015
- Oral compositions of proteinaceous medicaments303US 5,206,219 AApplied Analytical Industries, Inc. · 1993
- Abuse-proofed dosage system297US 7,776,314 B2GrüNenthal GmbH · 2010
- Method of reducing TNF.alpha. levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines288US 5,635,517 ACelgene Corporation · 1997
- Pharmaceutical formulation containing irritant212US 7,157,103 B2Euro-Celtique S. A. · 2007